Drug Profile

VS 7375

Alternative Names: GFH-375; GFH375/VS-7375; VS-7375

Latest Information Update: 27 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GenFleet Therapeutics
Developer GenFleet Therapeutics; Verastem Oncology
Class Antineoplastics; Small molecules
Mechanism of Action KRAS protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

19 Oct 2025 Efficacy and adverse events data from phase I/II clinical trials in Solid tumours released by Verastem Oncology
13 Aug 2025 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours released by Verastem Oncology
24 Jul 2025 VS 7375 receives Fast track designation status for Adenocarcinoma (First-line therapy, Late-stage disease, Metastatic disease) in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com